Nectero Therapeutics

Nectero Therapeutics is a private, clinical-stage biotech focused on addressing the significant unmet need in abdominal aortic aneurysm (AAA) management. Its lead program, the Nectero EAST® System, is an investigational endovascular treatment that delivers a proprietary mixture to the aneurysm site, aiming to strengthen the aortic wall and stabilize smaller AAAs, thereby preventing or delaying the need for major surgical interventions like EVAR or open repair. The company's vision is to transform the treatment paradigm for aneurysmal disease by offering an early-intervention option for the large population of patients currently under 'watchful waiting' surveillance. Founded in 2018 and based in Scottsdale, Arizona, Nectero is positioned to potentially revolutionize a standard of care that has seen little innovation for smaller aneurysms.

Nectero EAST® System: An endovascular platform for targeted delivery of a proprietary therapeutic mixture designed to biologically stabilize and strengthen the aortic wall in abdominal aortic aneurysms.

Direct competition is currently limited, as no approved pharmacologic or minimally invasive biologic stabilization therapy exists for AAA. The main competition is the entrenched standard of care: passive surveillance. Long-term, Nectero competes with the multi-billion dollar EVAR/open surgery device market by aiming to prevent patients from reaching that stage. Other companies may be exploring similar biologic approaches preclinically.